FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Insmed's Free Cash Flow for the
three
months ended in Dec. 2023 was $-133.0 Mil. Insmed's Revenue for the
three
months ended in Dec. 2023 was $83.7 Mil. Therefore, Insmed's FCF Margin % for the quarter that ended in Dec. 2023 was -158.88%.
As of today, Insmed's current FCF Yield % is -14.45%.
The historical rank and industry rank for Insmed's FCF Margin % or its related term are showing as below:
INSM'
s FCF Margin % Range Over the Past 10 Years
Min: -2773.68 Med: -188.35 Max: -137.56
Current: -180.05
During the past 13 years, the highest FCF Margin % of Insmed was -137.56%. The lowest was -2773.68%. And the median was -188.35%.
INSM's FCF Margin % is ranked worse than 53.15% of 1031
companies
in the Biotechnology industry
Industry Median: -148.24
vs INSM: -180.05
Insmed FCF Margin % Historical Data
The historical data trend for Insmed's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Insmed's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insmed FCF Margin % Distribution
For the Biotechnology industry and Healthcare sector, Insmed's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Insmed's FCF Margin % falls into.
Insmed FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Insmed's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insmed FCF Margin % Related Terms
Thank you for viewing the detailed overview of Insmed's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INSM has been successfully added to your 